Cryopreserved leukopaks from disease-state donors, currently focused on systemic lupus erythematosus (SLE) with active expansion into Crohn's, ulcerative colitis, celiac disease, rheumatoid arthritis, and multiple sclerosis. Each unit delivers a full leukopak (10 billion or more cells) from a single donor, screened against 14 infectious disease markers under 21 CFR 1271, with high-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, DP. Best fit: biomarker discovery, autoimmune drug screening, and cell therapy programs requiring disease-relevant immune dysregulation in vitro.
Plasma collected from systemic lupus erythematosus (SLE) donors via OrganaBio's HemaCenter apheresis subsidiary (wholly owned, FDA-registered). Each donor screened against 14 infectious disease markers under 21 CFR 1271 with NGS HLA typing across six genes. Sourced from OrganaBio's qualified, recallable donor pool. Best fit: autoantibody profiling, complement and inflammatory cytokine work, and disease-state-vs-healthy plasma comparisons in autoimmune research.
Serum from SLE donors, qualified under 21 CFR 1271 with the same 14-marker infectious disease screening (HIV-1/2, hepatitis B/C, HTLV-I/II, West Nile, Chagas plus CMV, EBV, alloantibodies) applied to all OrganaBio donors. Sourced from OrganaBio's recallable donor pool with NGS HLA typing across HLA-A, B, C, DR, DQ, DP. Best fit: SLE biomarker discovery, autoantibody panel development, and in vitro autoimmune research.
PBMCs from systemic lupus erythematosus (SLE) donors, isolated from leukopak material under cGMP-aligned conditions. Sourced from OrganaBio's qualified, recallable donor pool with 14-marker infectious disease screening per 21 CFR 1271 and high-resolution NGS HLA typing. OrganaBio reports an average 99.1% PBMC viability across more than 2,500 clinical samples. Best fit: autoimmune drug screening, biomarker discovery, and disease-state immune dysregulation studies.
B cells isolated from peripheral blood leukopaks via CD19+ immunomagnetic enrichment. Sourced from OrganaBio's 1,000+ qualified, recallable donor pool with 14-marker infectious disease screening and NGS HLA typing across HLA-A, B, C, DR, DQ, DP. Available as RUO and cGMP from the same donor pool under one quality system. Best fit: B-cell biology research, antibody-mediated cell therapy programs, and B-cell-targeted CGT preclinical work.
Monocytes isolated from peripheral blood leukopaks via CD14+ enrichment. Common starting material for macrophage and dendritic cell differentiation studies. Sourced from OrganaBio's recallable donor pool with full 14-marker infectious disease screening and high-resolution NGS HLA typing. Available as RUO and cGMP from one quality system. Best fit: macrophage polarization studies, monocyte-derived dendritic cell programs, and innate immunity research.
Mesenchymal stem cells from umbilical cord tissue, sourced through OrganaBio's GaiaGift perinatal subsidiary (wholly owned, FDA-registered). IRB-approved donor consent and 14-marker infectious disease screening per 21 CFR 1271. Available as RUO and cGMP from the same source pool. Best fit: regenerative medicine research, immunomodulation studies, and MSC-based cell therapy preclinical programs.
Mesenchymal stem cells from placental tissue, collected through GaiaGift's perinatal collection network with IRB-approved consent and 14-marker infectious disease screening per 21 CFR 1271. Available as RUO and cGMP from one source pool under one quality system. Best fit: regenerative medicine research, immunology studies, and placental-MSC-specific preclinical work.
T cells isolated from peripheral blood leukopaks via CD3+ enrichment. Sourced from OrganaBio's recallable donor pool with NGS HLA typing across six genes (HLA-A, B, C, DR, DQ, DP) and KIR genotyping where relevant. Available across RUO and cGMP grades from the same pool. Best fit: T-cell-based CGT programs, TCR engineering research, and immune cell therapy preclinical work.
PBMCs isolated from healthy-donor peripheral blood leukopaks. OrganaBio reports an average 99.1% post-thaw viability, PBMC recovery of 70% or more, and average composition of 60% T cells and 18% NK cells. 14-marker infectious disease screening per 21 CFR 1271 and NGS HLA typing on every donor. Available as RUO and cGMP from the same 1,000+ donor pool. Best fit: immunology research, drug screening, and CGT starting material across preclinical to clinical use.
NK cells isolated from peripheral blood leukopaks via CD56+ enrichment. Sourced from OrganaBio's qualified donor pool with KIR genotyping, relevant for NK-cell-therapy programs and KIR/HLA mismatching. 14-marker infectious disease screening and NGS HLA typing per donor. Best fit: NK-cell-based CGT programs, KIR-mismatch research, and innate-cell-therapy preclinical work.
Cryopreserved leukopaks from healthy donors, 10 billion or more cells per single-donor unit. Sourced from OrganaBio's 1,000+ qualified, recallable donor pool via HemaCenter (wholly owned, FDA-registered apheresis subsidiary). 14-marker infectious disease screening, NGS HLA typing across HLA-A, B, C, DR, DQ, DP, and KIR genotyping. Available as RUO and cGMP from the same pool. Best fit: downstream immune cell isolation, CGT starting material, and research programs needing predictable per-experiment cell counts.
Fresh, non-mobilized leukopaks from healthy donors, delivered for same-day or next-day downstream isolation. 10 billion or more cells per single-donor unit. Sourced from OrganaBio's recallable donor pool via HemaCenter (wholly owned, FDA-registered). 14-marker infectious disease screening and NGS HLA typing on every donor. Best fit: programs requiring fresh starting material for immediate isolation rather than cryopreserved.
T cells isolated from cord blood, collected via OrganaBio's GaiaGift perinatal subsidiary (wholly owned, FDA-registered) under IRB-approved consent and 14-marker infectious disease screening per 21 CFR 1271. Available as RUO and cGMP from the same source pool. Best fit: cord-blood T-cell biology, allogeneic CGT preclinical work, and research programs needing cord-blood-specific T cell phenotypes.
NK cells from cord blood, sourced through GaiaGift with IRB-approved donor consent and 14-marker infectious disease screening. Cord blood NK cells offer different biological profiles than peripheral blood NK cells, including more naive phenotypes useful for certain CGT programs. KIR genotyping available. Best fit: cord-blood NK CGT programs, NK biology research, and allogeneic NK cell therapy preclinical work.
CD34+ hematopoietic stem cells from cord blood, with cGMP manufacturing service launched in 2024 under OrganaBio's quality system. Sourced via GaiaGift (wholly owned, FDA-registered) under IRB-approved consent and 14-marker infectious disease screening per 21 CFR 1271. NGS HLA typing across HLA-A, B, C, DR, DQ, DP supports allogeneic donor matching. Best fit: HSCT research, gene therapy programs, and allogeneic CGT starting material where lower GvHD risk and easier HLA matching matter.
Fresh whole cord blood units from GaiaGift (wholly owned, FDA-registered), delivered for downstream isolation, cell expansion, or research applications. Each unit collected under IRB-approved consent with 14-marker infectious disease screening per 21 CFR 1271. Best fit: research programs requiring fresh cord blood as starting material for in-house isolation rather than pre-isolated cells.
Supply Brain is OrganaBio's editorial on cell and gene therapy supply chain, donor sourcing, sample processing, and starting materials. Posts cover regulatory frameworks, donor recallability, characterization protocols, and the operational realities behind clinical-grade leukopaks, PBMCs, and stem cells. Written by OrganaBio's scientific and operational team.
OrganaBio Type 1 diabetes PBMC donors with documented autoantibody status, HLA typing, C-peptide status, disease duration, and HbA1c for islet antigen-specific T cell research, Treg therapy programs, and T1D drug screening.
OrganaBio rheumatoid arthritis PBMC donors with documented DAS28 scores, serostatus (RF/anti-CCP), medication washout, and HLA typing for translational immunology research and drug candidate screening.
A regulatory guide to qualifying a cell therapy starting material supplier for IND submission: what FDA expects, GTP vs. cGMP requirements, the supplier swap comparability problem, and a 25-point supplier audit checklist.
A practical decision guide comparing whole blood, buffy coat, and leukopak as PBMC source formats: yield, purity, cost per usable cell, when each format is the right choice, and how processing time affects quality across all three.
KIR genotype is one of the most predictive donor variables for NK cell functional activity. OrganaBio performs KIR genotyping on every leukopak donor — a standard no other supplier offers — enabling prospective donor selection for allogeneic NK programs.
A direct comparison of OrganaBio and AllCells (Discovery Life Sciences) across processing model, viability specs, GMP quality systems, same-donor continuity, and organizational focus for cell therapy starting material programs.
OrganaBio’s SLE donor pool provides PBMC material from systemtic lupus erythematosus donors with documented SLEDAI scores, HLA typing, medication washout status, and organ involvement annotation for immunology research.
PBMC Functional Fitness: Why Viability Alone Doesn’t Tell You What You Need to Know The COA arrives showing 95% viability. The cells thaw cleanly, the
The CNS Autoimmune Boundary Your Healthy Donor Data Can’t Cross Multiple sclerosis (MS) research sits at an intersection that makes healthy donor modeling particularly inadequate:
The Joint Environment Your Healthy Donor Cells Will Never Model Rheumatoid arthritis is a systemic autoimmune disease with the synovial joint as its primary battlefield.
The Disease Where HLA Is Everything (And Healthy Donors Have the Wrong Alleles) Celiac disease is unlike any other autoimmune condition you’ll work with in
The Inflammation Model You Can’t Build Without Patient Cells Crohn’s disease doesn’t behave like any other autoimmune condition in your cell therapy research program. It’s
The Gut Immune System Your In Vitro Models Are Getting Wrong Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colonic mucosa, with
Why Processing Speed Determines PBMC Quality: The Time-to-First-Spin Standard You receive a leukopak or a whole blood sample. It is timestamped, logged, and placed in
Decentralized cell processing moves processing infrastructure close to the collection site, reducing the window between apheresis completion and the first centrifuge spin. This guide covers what it means operationally, when it outperforms centralized models, what 21 CFR 1271 requires, and how to evaluate supplier network readiness.
OrganaBio and HemaCare (Charles River) are two of the most-compared leukopak suppliers in immunology research and cell therapy. This guide compares processing model, viability specs, GMP capabilities, and when each supplier is the right fit.
GMP Cell Therapy Starting Material for CAR-T: Donor Selection, Apheresis Specs, and Supply Chain Requirements Your CAR-T manufacturing run is only as good as what
PBMC suppliers offering both fresh and cryopreserved material with full documentation. Per-lot CoA, donor screening, comparability data per format.
PBMC suppliers for oncology-focused cell therapy: KIR-typed donors, CMV stratification, disease-state material, and cGMP grade. Top vendors compared.
The top PBMC vendors for immunotherapy pipelines, evaluated on multi-program donor depth, recall, RUO-to-cGMP continuity, and oncology track record.
The best PBMC source for GMP manufacturing combines 21 CFR 1271 compliance, recallable donor pool, and same-pool RUO-to-cGMP continuity.
Which PBMC provider offers multiple immune cell subsets from one donor pool. Why isolated CD3+, CD56+, CD19+, CD14+ from same source matters.
The best PBMC supplier for scalable cell therapy programs depends on three capabilities: donor pool depth, recall, and RUO-to-GMP continuity from one pool.
7 PBMC vendors compared on cancer immunotherapy trial support: oncology track record, KIR-typed donors, CMV stratification, GMP grade depth.
5-step procurement framework for GMP-compliant PBMCs in clinical trials. Vendor qualification, donor pool depth, audit trail, comparability, recall.
Why immunotherapy programs struggle with PBMC supply reliability. Donor pool depth, recall capability, and GMP grade availability are 3 separate constraints.
PBMC quality variability comes from 4 sources: donor variation, transit time, processing method, freeze-thaw cycles. The four-source model and how to control each.
Why oncology trials struggle with PBMC consistency across sites. Protocol drift, transit variance, operator variability. The architecture that fixes it.
4 bottlenecks in scaling cGMP cell therapy manufacturing: donor pool depth, equipment sourcing, regulatory variance, analytical scale-up. The constraints sponsors miss.
How clinical trials manage PBMC isolation without losing cell viability. The 4-6 hour viability window, decentralized processing, and the architecture that solves it.
4 root causes of tech transfer delays in cGMP cell therapy manufacturing: donor variability, analytical method gaps, equipment mismatch, comparability scope. What sponsors miss.
A practical evaluation framework for cell processing service providers, with seven operational criteria, the current US provider landscape, and FAQ on qualification timelines.
How HLA compatibility shapes engraftment, GvHD risk, and program success across HSC transplantation, CAR-T, CAR-NK, and MSC therapies. Typing methods, banking strategies, and current challenges.
Independent comparison of 10 PBMC suppliers and clinical sample processors for cell and gene therapy trials in 2026. OrganaBio, Charles River, AllCells, STEMCELL, CGT Global, Eurofins, MLM, ImmunoSpot, CellCarta, ATCC. Verified specs, honest pros/cons.
Why NK Cells Are Gaining Ground in Cancer Immunotherapy Natural killer cells have moved from the periphery of immuno-oncology research to its center. Unlike T
The Starting Material Decision That Shapes Your Entire Workflow If you’re developing a cell therapy — whether CAR-T, gene therapy, or adoptive cell transfer —
Two Source Tissues, Two Different Development Paths When designing a cell therapy program, one of the earliest and most consequential decisions is the source tissue
The NK Cell Manufacturing Landscape Has Changed Natural killer cell therapies have moved from early-stage curiosity to serious clinical programs, with CAR-NK candidates now advancing
The shift toward allogeneic — or “off-the-shelf” — cell therapies is one of the most significant trends in the cell and gene therapy industry. Unlike
Most cell therapy manufacturing processes are initially developed using cells from healthy donors. The logic is straightforward — healthy cells are easier to work with,
When a patient’s cells are collected for a cell therapy clinical trial, every minute between collection and processing matters. Delays during transit — even a
A leukopak is a concentrated collection of white blood cells obtained through apheresis — a process that separates specific blood components from a donor and
The Uncomfortable Truth About Your “Perfect” Healthy Donors Here’s a question that should keep every cell therapy developer awake at night: Why are you developing
Why scientists need a procurement model If you can’t explain total cost of ownership (TCO) in lab terms, procurement will do it for you –
Teams will optimize PBMC isolation for weeks and then improvise the samples thaw process. That’s backwards. Thaw is where you either protect what you banked
Cord blood is a rich source of hematopoietic stem cells (HSCs), which are immature cells that can develop into all types of blood cells. This
Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an
Cell and gene therapy development grapples with a paradox: fresh starting material is often equated with higher-quality drug products, but cryopreservation is crucial for scale-up.
Sponsors conducting clinical trials require the collection of participant blood samples at specific intervals and over a rolling period, necessitating an experienced cell processing solutions
Advanced cell-based therapies, such as chimeric antigen receptor (CAR)-T cell therapies, are changing the landscape of healthcare, expanding treatment options for patients beyond previous standards
Managing Director, CPC Services
Andrew joins OrganaBio as a project manager with varied experience in project management, client relations, and process improvement.
Prior to OrganaBio, Andrew was a client relations manager for the cGMP nucleic acids business unit at Aldevron, coordinating and managing contracts at each stage of the contract lifecycle in support of cell and gene therapy program development. Andrew supported small- and large-scale biotechnology and pharmaceutical clients anywhere from pre-IND work through commercial supply chain establishment. Before Aldevron, Andrew was a project manager for the commercialization and business development department for Sanford Health, a worldwide hospital institution. At Sanford Health, Andrew helped manage medical device patent and prototype development efforts for employee innovations primarily in the cardiovascular, neurovascular, and software spaces. Andrew was also an engineer for Atirix Medical Systems and supported the buildout of automated analysis worksheets to streamline radiology department quality control procedures.
Andrew received his Bachelor of Science in Physics from Minnesota State University Moorhead and his Master of Science in Biomedical Engineering from the University of Minnesota. At the University of Minnesota, Andrew was part of the Center for Magnetic Resonance Research, assisting efforts to automate MRI dataset registration and workflow improvement.
Associate Director, QC and Analytical Development
Michael Dee has spent the last 17 years researching the immune system. Initially studying the recombinant cytokine IL-2 and its role in T cell subset differentiation and function at the University of Miami. He also helped elucidate the lower level of TCR diversity of T regs required to prevent autoimmunity in mice. Michael also supported construction, cloning, production, purification, and testing both in vitro and in vivo a novel IL-2/IL2Rα complex currently under clinical development with BMS. Michael also was a member of the department of immunology’s program project delineating the effect of a novel Eg7GP96 heat shock protein vaccine on tumor immunity.
While at Immunity Bio (formerly Altor Biosciences), he helped to characterize over 20 novel drugs for immune modulation and treatment of cancer. After Immunity Bio, Michael was a founding team member of HCW Biologics, where he continued his role in design and initial production and characterization of several novel biologics. He has experience with proof of principle experiments with the generation CAR-NK and CAR T cells. His research at HCW was highlighted by his discovery of a process using novel biologics to activate and expand CIML NK cells. The process and rights were sold to Wugen and is currently in Phase I clinical trials. He also is listed as an Inventor on patent number: US20210268022A1 on method of activating regulatory T cells.
Senior Cell Processing Specialist
Senior Bioprocess Scientist
Director, Regional Scientific Sales
Marisa has experience leading marketing and sales life sciences programs for over a decade. Originally a lab researcher, she made the jump to marketing & sales in life sciences and never looked back.
At OrganaBio, she connects cell therapy developers on the West coast and in Asia with the healthy donor starting materials they need to develop their therapies. Prior to OrganaBio, she was the cell therapy marketing lead at Invetech, heading the launch of the company’s first cell therapy product. Marisa has led marketing programs at clinical supply companies Sherpa Clinical Packaging and PCI Pharma Services. In her spare time, Marisa enjoys traveling, eating, and pretending she’s a tennis player. She has a Bachelor of Arts in Biology from Reed College and an MBA from Portland State University.
Senior Director, Tissue Procurement
Vice President, Operations
Vice President, Quality & Regulatory Affairs
Senior Director, Quality Assurance
Danielle Smyla, M.S., brings 14 years of Quality Assurance and GMP experience in the Biotechnology and Medical Device industries. Ms. Smyla is an established Quality Leader with expertise in the implementation, management and continuous improvement of Quality Management Systems for GMP operations.
Prior to joining OrganaBio, Danielle was a key member of the Quality Management team at Canon BioMedical, where she led the cross-functional development and implementation of their Quality Management System. She also managed a team of Quality Specialists and Sr. Specialists, coaching them in the implementation, management and identification of improvements to quality processes.
Ms. Smyla’s Quality-focused career is complimented by valuable hands-on experience in GMP product manufacturing, as well as R&D laboratory experimentation and formulation work in support of product development.
Danielle has earned a Master’s in Biotechnology from the Johns Hopkins University and a Bachelor of Science in Chemistry from the George Washington University.
Lab Director
Sarah Alter, Ph.D., is Laboratory Director at OrganaBio, LLC, where she provides technical leadership across laboratory operations, process development, product manufacturing, and clinical sample processing services supporting cell and gene therapy developers worldwide. She brings more than 20 years of immunology and translational research experience spanning autoimmunity, oncology, and infectious disease.
Since joining OrganaBio in 2018, Dr. Alter has progressed through roles of increasing responsibility, first as Director of Immunology, leading development and manufacturing of human-derived immune cell products for immuno-oncology partners and clients; then as Senior Director of Scientific Affairs, where she served as immunology subject matter expert and shaped scientific strategy across new product launches, market analyses, and client engagements. She also served as founding Managing Director of HemaCenter, LLC, OrganaBio’s FDA-registered leukapheresis collection subsidiary, where she stood up operations, recruited the medical team, and authored governing protocols and SOPs.
Earlier in her career, Dr. Alter led preclinical R&D for IL-15–based immunotherapies at Altor BioScience (now ImmunityBio), contributing to programs that advanced into the clinic and co-authoring numerous peer-reviewed publications. She holds a Ph.D. in Immunology from the University of Miami Miller School of Medicine and an M.Sc. in Microbiology from Florida Atlantic University, and is a registered Patent Agent licensed to practice before the U.S. Patent and Trademark Office.
Vice President, Sales
Director, Quality Systems
Oscar Robles has over thirty years of experience in pharmaceutical and medical device industries. His main areas of expertise are in Quality Systems, Quality Assurance, Manufacturing Systems Validation, Computerized Systems Validation, implementation of GxP Computerized Systems and ERP Systems such as TrackWise, Electronic Document Management, JDEwards, SAP, and Oracle. Prior to joining OrganaBio, Oscar was a member of the Quality Management team at Apotex – Aveva Drug Delivery Systems for ten years. Oscar has earned a Master’s in Business Administration from Nova Southeastern University and a Bachelor of Science in Electrical Engineering from Florida International University.
Tell us what you need and our team will follow up within one business day.
OrganaBio has acquired substantially all operating assets of Excellos Inc., creating a coast-to-coast CTDMO with cGMP capabilities across Miami and San Diego under one quality management system.
